Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct;14(10):346-351.
doi: 10.5489/cuaj.6268.

A Canadian approach to the regionalization of testis cancer: A review

Affiliations
Review

A Canadian approach to the regionalization of testis cancer: A review

Gregory J Nason et al. Can Urol Assoc J. 2020 Oct.

Abstract

At the Canadian Testis Cancer Workshop, the rationale and feasibility of regionalization of testis cancer care were discussed. The two-day workshop involved urologists, medical and radiation oncologists, pathologists, radiologists, physician's assistants, residents and fellows, and nurses, as well as patients and patient advocacy groups.This review summarizes the discussion and recommendations of one of the central topics of the workshop - the centralization of testis cancer in Canada. It was acknowledged that non-guideline-concordant care in testis cancer occurs frequently, in the range of 18-30%. The National Health Service in the U.K. stipulates various testis cancer care modalities be delivered through supra-regional network. All cases are reviewed at a multidisciplinary team meeting and aspects of care can be delivered locally through the network. In Germany, no such network exists, but an insurance-supported online second opinion network was developed that currently achieves expert case review in over 30% of cases. There are clear benefits to regionalization in terms of survival, treatment morbidity, and cost. There was agreement at the workshop that a structured pathway for diagnosis and treatment of testis cancer patients is required.Regionalization may be challenging in Canada because of geography; independent administration of healthcare by each province; physicians fearing loss of autonomy and revenue; patient unwillingness to travel long distances from home; and the inability of the larger centers to handle the ensuing increase in volume. We feel the first step is to identify the key performance indicators and quality metrics to track the quality of care received. After identifying these metrics, implementation of a "networks of excellence" model, similar to that seen in sarcoma care in Ontario, could be effective, coupled with increased use of health technology, such as virtual clinics and telemedicine.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Dr. Wood has been an advisory board member (with no compensation) for Astellas, Pfizer, and Novartis; and has participated in clinical trials supported by Aragon, AstraZeneca, BMS, Exelixis, Merck, Pfizer, and Roche. Dr. Rendon has been an advisory board and speakers’ bureau member for, and has received honoraria from Abbvie, Amgen, Astellas, AstraZeneca, Bayer, Ferring, Jansen, and Sanofi. Dr. Kollmannsberger has been an advisory board member for Astellas, BMS, Novartis, Pfizer, and Sanofi; has received honoraria from BMS, Novartis, and Pfizer; and has participated in clinical trials supported by Astellas, AstraZeneca, BMS, Janssen, Merck, Novartis, Pfizer, and Sanofi. Dr. Jewett has been an advisory board member for Pfizer and Theralase Tech; has received honoraria from Olympus, Pfizer, and Theralase Tech; and holds investments in Theralase Tech. Dr. Chung has received honoraria from Sanofi and has participated in clinical trials supported by AbbVie. The remaining authors report no competing personal or financial interests related to this work.

References

    1. Canadian Cancer Statistics. A 2018 special report on cancer incidence by stage. [Accessed May 12, 2020]. Available at: www.cancer.ca.
    1. Wood L, Kollmannsberger C, Jewett M, et al. Canadian consensus guidelines for the management of testicular germ cell cancer. Can Urol Assoc J. 2010;4:e19–38. doi: 10.5489/cuaj.815\. - DOI - PMC - PubMed
    1. Stephenson A, Eggener SE, Bass EB, et al. Diagnosis and treatment of early stage testicular cancer: AUA guideline. J Urol. 2019;202:272–81. doi: 10.1097/JU.0000000000000318. - DOI - PubMed
    1. Albers P, Albrecht W, Algaba F, et al. European Association of Urology. Guidelines on testicular cancer: 2015 update. Eur Urol. 2015;68:1054–68. doi: 10.1016/j.eururo.2015.07.044. - DOI - PubMed
    1. Paffenholz P, Heidegger IM, Kuhr K, et al. Non-guideline-concordant treatment of testicular cancer is associated with reduced relapse-free survival. Clin Genitourin Cancer. 2017;(17):S1558–7673. 30273–2. - PubMed

LinkOut - more resources